|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CD109 |
Gene summary for CD109 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CD109 | Gene ID | 135228 |
| Gene name | CD109 molecule | |
| Gene Alias | CPAMD7 | |
| Cytomap | 6q13 | |
| Gene Type | protein-coding | GO ID | GO:0000768 | UniProtAcc | Q6YHK3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 135228 | CD109 | CA_HPV_2 | Human | Cervix | CC | 8.22e-04 | 2.97e-01 | 0.0391 |
| 135228 | CD109 | CCI_1 | Human | Cervix | CC | 3.11e-12 | 1.47e+00 | 0.528 |
| 135228 | CD109 | Tumor | Human | Cervix | CC | 2.04e-02 | 2.21e-01 | 0.1241 |
| 135228 | CD109 | sample3 | Human | Cervix | CC | 2.49e-03 | 2.62e-01 | 0.1387 |
| 135228 | CD109 | H2 | Human | Cervix | HSIL_HPV | 4.09e-05 | -1.66e-01 | 0.0632 |
| 135228 | CD109 | T3 | Human | Cervix | CC | 4.56e-07 | 2.35e-01 | 0.1389 |
| 135228 | CD109 | LZE2T | Human | Esophagus | ESCC | 1.40e-02 | 3.36e-01 | 0.082 |
| 135228 | CD109 | LZE4T | Human | Esophagus | ESCC | 1.57e-16 | 3.99e-01 | 0.0811 |
| 135228 | CD109 | LZE24T | Human | Esophagus | ESCC | 3.88e-04 | -4.32e-02 | 0.0596 |
| 135228 | CD109 | LZE6T | Human | Esophagus | ESCC | 5.42e-03 | -3.94e-02 | 0.0845 |
| 135228 | CD109 | P2T-E | Human | Esophagus | ESCC | 7.05e-13 | 2.04e-01 | 0.1177 |
| 135228 | CD109 | P4T-E | Human | Esophagus | ESCC | 1.90e-17 | 6.25e-01 | 0.1323 |
| 135228 | CD109 | P5T-E | Human | Esophagus | ESCC | 4.03e-26 | 5.18e-01 | 0.1327 |
| 135228 | CD109 | P8T-E | Human | Esophagus | ESCC | 5.98e-06 | 1.85e-01 | 0.0889 |
| 135228 | CD109 | P9T-E | Human | Esophagus | ESCC | 2.47e-09 | 2.68e-01 | 0.1131 |
| 135228 | CD109 | P10T-E | Human | Esophagus | ESCC | 2.54e-16 | 3.07e-01 | 0.116 |
| 135228 | CD109 | P11T-E | Human | Esophagus | ESCC | 1.85e-06 | 6.39e-01 | 0.1426 |
| 135228 | CD109 | P12T-E | Human | Esophagus | ESCC | 2.55e-22 | 5.43e-01 | 0.1122 |
| 135228 | CD109 | P15T-E | Human | Esophagus | ESCC | 2.39e-17 | 6.11e-01 | 0.1149 |
| 135228 | CD109 | P16T-E | Human | Esophagus | ESCC | 1.46e-04 | 3.26e-04 | 0.1153 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
| GO:005254710 | Cervix | CC | regulation of peptidase activity | 112/2311 | 461/18723 | 6.70e-13 | 3.08e-10 | 112 |
| GO:005254810 | Cervix | CC | regulation of endopeptidase activity | 103/2311 | 432/18723 | 1.89e-11 | 5.14e-09 | 103 |
| GO:00085446 | Cervix | CC | epidermis development | 83/2311 | 324/18723 | 3.91e-11 | 8.54e-09 | 83 |
| GO:00435884 | Cervix | CC | skin development | 71/2311 | 263/18723 | 8.04e-11 | 1.46e-08 | 71 |
| GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
| GO:00302164 | Cervix | CC | keratinocyte differentiation | 42/2311 | 139/18723 | 1.74e-08 | 1.28e-06 | 42 |
| GO:004586110 | Cervix | CC | negative regulation of proteolysis | 80/2311 | 351/18723 | 2.88e-08 | 1.98e-06 | 80 |
| GO:00099137 | Cervix | CC | epidermal cell differentiation | 53/2311 | 202/18723 | 5.48e-08 | 3.25e-06 | 53 |
| GO:003009910 | Cervix | CC | myeloid cell differentiation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
| GO:00506787 | Cervix | CC | regulation of epithelial cell proliferation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
| GO:00513469 | Cervix | CC | negative regulation of hydrolase activity | 81/2311 | 379/18723 | 4.27e-07 | 1.67e-05 | 81 |
| GO:19030349 | Cervix | CC | regulation of response to wounding | 44/2311 | 167/18723 | 6.33e-07 | 2.31e-05 | 44 |
| GO:00104669 | Cervix | CC | negative regulation of peptidase activity | 60/2311 | 262/18723 | 1.27e-06 | 4.34e-05 | 60 |
| GO:004593610 | Cervix | CC | negative regulation of phosphate metabolic process | 88/2311 | 441/18723 | 2.92e-06 | 8.27e-05 | 88 |
| GO:001056310 | Cervix | CC | negative regulation of phosphorus metabolic process | 88/2311 | 442/18723 | 3.21e-06 | 8.77e-05 | 88 |
| GO:00456822 | Cervix | CC | regulation of epidermis development | 22/2311 | 65/18723 | 5.56e-06 | 1.38e-04 | 22 |
| GO:001095110 | Cervix | CC | negative regulation of endopeptidase activity | 56/2311 | 252/18723 | 7.43e-06 | 1.74e-04 | 56 |
| GO:00456042 | Cervix | CC | regulation of epidermal cell differentiation | 20/2311 | 58/18723 | 1.07e-05 | 2.33e-04 | 20 |
| GO:004232610 | Cervix | CC | negative regulation of phosphorylation | 77/2311 | 385/18723 | 1.09e-05 | 2.38e-04 | 77 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CD109 | SNV | Missense_Mutation | rs137899447 | c.445N>T | p.Arg149Cys | p.R149C | Q6YHK3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
| CD109 | SNV | Missense_Mutation | c.3391C>G | p.Leu1131Val | p.L1131V | Q6YHK3 | protein_coding | deleterious(0.01) | benign(0.062) | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD | |
| CD109 | SNV | Missense_Mutation | rs745425108 | c.917C>T | p.Ser306Leu | p.S306L | Q6YHK3 | protein_coding | tolerated(0.16) | benign(0.013) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| CD109 | SNV | Missense_Mutation | c.2918C>G | p.Ser973Cys | p.S973C | Q6YHK3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CD109 | SNV | Missense_Mutation | c.3850G>C | p.Asp1284His | p.D1284H | Q6YHK3 | protein_coding | deleterious(0.02) | possibly_damaging(0.813) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CD109 | SNV | Missense_Mutation | rs137899447 | c.445C>T | p.Arg149Cys | p.R149C | Q6YHK3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CD109 | SNV | Missense_Mutation | rs776870550 | c.627A>T | p.Gln209His | p.Q209H | Q6YHK3 | protein_coding | deleterious(0.02) | possibly_damaging(0.722) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CD109 | SNV | Missense_Mutation | novel | c.2636C>T | p.Thr879Ile | p.T879I | Q6YHK3 | protein_coding | tolerated(0.09) | benign(0.101) | TCGA-BH-A0HB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
| CD109 | SNV | Missense_Mutation | c.1090N>G | p.Leu364Val | p.L364V | Q6YHK3 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-C8-A12P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CD109 | SNV | Missense_Mutation | rs202157387 | c.79N>T | p.Arg27Trp | p.R27W | Q6YHK3 | protein_coding | deleterious(0.01) | possibly_damaging(0.727) | TCGA-E2-A2P5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |